Andere Sprachen Roivant Sciences Ltd.

Aktien

A3C4MS

BMG762791017

ROIV

Realtime-Estimate Cboe BZX Andere Börsenplätze 16:49:45 29.04.2024			% 5 Tage	% 1. Jan.
11,08 ^USD	+0,41 %		+4,29 %	-1,56 %

05.04.	Arbutus Biopharma erhält günstigen Gerichtsbeschluss in Moderna-Patentklage	MT
04.04.	Moderna erleidet Rückschlag in Klage von Arbutus	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit	05.04.
Moderna Suffers Setback in Lawsuit by Arbutus	04.04.
Moderna shares fall after judge sides with Arbutus in patent fight	03.04.
Tesla, UnitedHealth Group fall; Roivant, Valero rise, Tuesday, 4/2/2024	02.04.
Roivant Sciences : NIU Phase 2 Topline Results	02.04.
Roivant Sciences Says Study of Potential Uveitis Treatment Meets Endpoints; Launches Stock Repurchase; Shares Rise	02.04.
Roivant Sciences Ltd. announces an Equity Buyback for $1,500 million worth of its shares.	02.04.
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million	02.04.
Roivant's anti-inflammatory drug succeeds in mid-stage study	02.04.
Roivant and Priovant Therapeutics Announce Positive Results from the Phase 2 Study for Brepocitinib in NIU	02.04.
Roivant Sciences Ltd. authorizes a Buyback Plan.	02.04.
Roivant Sciences Ltd.(NasdaqGS:ROIV) added to S&P 1000	01.04.
Roivant Sciences Ltd.(NasdaqGS:ROIV) added to S&P 400 - Biotechnology	01.04.
Roivant Sciences Ltd.(NasdaqGS:ROIV) added to S&P 400 Health Care	01.04.
Roivant Sciences Ltd.(NasdaqGS:ROIV) added to S&P Composite 1500	01.04.
Roivant Sciences Ltd.(NasdaqGS:ROIV) added to S&P 400	01.04.
Sunrun, Roivant Shares Rise Ahead of Inclusion in S&P SmallCap, MidCap Indexes	27.03.
Roivant Sciences Swings to Fiscal Q3 Earnings as Net Revenue Rises	13.02.
Roivant Sciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	13.02.
Stocks Decline Pre-Bell Ahead of Key Inflation Data; Asia Mixed, Europe Down	13.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Roivant Sciences Ltd.

Aktien

A3C4MS

BMG762791017

ROIV

Andere Sprachen

Filter